

Applicant: Smith et al.  
Application No: 09/890,927  
Docket No: 1188-67 PCT/US  
Page 2

**Amendments to the Claims:**

1-4. cancelled.

5. (currently amended) The compound of claim 27 wherein:  
substituent(s) on E is(are) independently substituted or unsubstituted alkyl, halogen, hydroxy, ester, -S-alkyl, NO<sub>2</sub> or SO<sub>2</sub>;  
substituent(s) on G is(are) independently substituted or unsubstituted alkyl, alkenyl, alkynyl, cycloalkyl, halogen, amide, amine, hydroxy, sulfonyl, sulfonamide, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amine, -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-heterocycle, or -(CH<sub>2</sub>)<sub>n</sub>-O-(CH<sub>2</sub>)<sub>m</sub>-amide, wherein n and m are independently 0, 1, 2, 3, 4 or 5; and  
substituent(s) on J is(are) independently ~~substituted alkyl-methyl~~ halogen, ether, -S-alkyl, or -S-aryl.


6. (original) The compound of claim 5, wherein:  
substituent(s) on E and J is(are) halogen; and  
substituent(s) on G is(are) halogen and/or substituted alkyl.

7-19 (cancelled)

20. (previously presented) A composition comprising a compound according to claim 27 in a pharmaceutically acceptable carrier therefor.

21-26. (canceled)

27. (previously presented) A compound having the structure:



Applicant: Smith et al.  
Application No: 09/890,927  
Docket No: 1188-67 PCT/US  
Page 3

and pharmaceutically acceptable salts thereof, wherein:

D is hydrogen or lower alkyl;

E is substituted or unsubstituted phenyl;

G is substituted or unsubstituted phenyl; and

J is substituted phenyl, comprising one or more substituents selected from the group consisting of methyl, ~~substituted alkyl~~ substituted by one or more substituents selected from cycloalkyl, cycloalkenyl, aryl, heterocycle, cyano, cyanomethyl, nitro, amino, amide, amidine, hydroxyl, carboxyl, carbamate, ether, ester sulfonyl, sulfonamide and mercapto, halogen, ether, -S-alkyl, or -S-aryl.

28. (canceled)